5 completed, 3 recruiting, 2 active not recruiting, 1 approved for marketing. 4 Phase 2, 3 Phase 3, 2 Not applicable, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Completed 3, Recruiting 1 |
| Phase 3 | 3 | Active not recruiting 1, Completed 1, Unknown 1 |
| Not applicable | 2 | Active not recruiting 1, Recruiting 1 |
| Phase 1 | 1 | Completed 1 |
Follow Membranoproliferative Glomerulonephritis: new trials by email Literature Review of Membranoproliferative Glomerulonephritis trials Research Report on Membranoproliferative Glomerulonephritis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Developing a Pipeline to Employ RNA-Seq as a Complementary Diagnostic Tool in Rare Diseases Skin biopsy - Atypical Hemolytic Uremic Syndrome, Membranoproliferative Glomerulonephritis | Not applicable | Recruiting | Mario Negri Institute for Pharmacological Research | 105 | 2024-02-21 | 2026-03-23 |
| New Analytic Tools for aHUS and C3G Diagnosis C3NEF assay - Hemolytic-Uremic Syndrome, Membranoproliferative Glomerulonephritis | Not applicable | Active not recruiting | Mario Negri Institute for Pharmacological Research | 180 | 2023-07-01 | 2026-03-23 |
| An Open-Label, Nonrandomized, Multicenter Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan in Participants With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis Pegcetacoplan - C3G, IC-MPGN | Phase 3 | Active not recruiting | Apellis Pharmaceuticals, Inc. | 100 | 2023-05-29 | 2026-04-02 |
| Phase III Study Assessing the Efficacy and Safety of Pegcetacoplan in Patients With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis Pegcetacoplan, Placebo - C3G, IC-MPGN | Phase 3 | Completed | Apellis Pharmaceuticals, Inc. | 124 | 2021-11-12 | 2026-01-29 |
| Study Assessing the Safety and Efficacy of Pegcetacoplan in Post-Transplant Recurrence of C3G or IC-MPGN Pegcetacoplan - C3G, IC-MPGN | Phase 2 | Completed | Apellis Pharmaceuticals, Inc. | 13 | 2021-09-07 | 2026-04-21 |
| Evaluation of a Renin Inhibitor, Aliskiren, Compared to Enalapril, in C3 Glomerulopathy Aliskiren, Enalapril - C3 Glomerulopathy, Membranoproliferative Glomerulonephritis | Phase 2 | Recruiting | Region Skane | 30 | 2020-10-01 | 2025-06-22 |
| Daratumumab in Treatment of PGNMID and C3 GN Daratumumab - Membranoproliferative Glomerulonephritis | Phase 2 | Completed | Fernando Fervenza | 12 | 2017-09-07 | 2022-08-31 |
| Effect of Rituximab in Treatment of Membranoproliferative Glomerulonephritis Rituximab, Cyclosporin - Membranoproliferative Glomerulonephritis | Phase 3 | Unknown | Assiut University | 30 | 2017-07-01 | 2017-06-16 |
| Eculizumab in Primary MPGN Eculizumab - Membranoproliferative Glomerulonephritis | Phase 2 | Completed | Mario Negri Institute for Pharmacological Research | 10 | 2014-03-01 | 2018-01-17 |
| Eculizumab Therapy for Dense Deposit Disease and C3 Nephropathy Eculizumab - Dense Deposit Disease, Membranoproliferative Glomerulonephritis | Phase 1 | Completed | Columbia University | 6 | 2010-07-01 | 2019-02-19 |
| National Registry of Rare Kidney Diseases Adenine Phosphoribosyltransferase Deficiency, AH Amyloidosis | Recruiting | UK Kidney Association | 35000 | 2009-11-06 | 2023-10-04 | |
| C3G/Primary IC-MPGN EAP Pegcetacoplan - C3G, IC-MPGN | Approved for marketing | Apellis Pharmaceuticals, Inc. | 2025-11-06 |
Glomerulonephritis, Membranoproliferative (12) · Atypical Hemolytic Uremic Syndrome (2) · Nephrotic Syndrome (2) · Polycystic Kidney, Autosomal Dominant (2) · Adenine phosphoribosyltransferase deficiency (1) · Bartter Syndrome (1) · Calciphylaxis (1) · Cystinosis (1) · Cystinuria (1) · Dent Disease (1) · Denys-Drash Syndrome (1) · Diabetes Insipidus, Nephrogenic (1) · Fabry Disease (1) · Fibromuscular Dysplasia (1) · Gitelman Syndrome (1)
Female Urogenital Diseases (12) · Female Urogenital Diseases and Pregnancy Complications (12) · Glomerulonephritis (12) · Immune System Diseases (12) · Kidney Diseases (12) · Male Urogenital Diseases (12) · Nephritis (12) · Urogenital Diseases (12) · Urologic Diseases (12) · Anemia (3) · Anemia, Hemolytic (3) · Blood Platelet Disorders (3) · Cytopenia (3) · Hematologic Diseases (3) · Hemic and Lymphatic Diseases (3)
pegcetacoplan (4) · eculizumab (2) · Cyclosporine (1) · Enalapril (1) · Rituximab (1) · aliskiren (1) · daratumumab (1)
Apellis Pharmaceuticals, Inc. (4) · Mario Negri Institute for Pharmacological Research (3) · Assiut University (1) · Columbia University (1) · Fernando Fervenza (1) · Region Skane (1) · UK Kidney Association (1)
Italy (6) · United States (5) · United Kingdom (4) · Argentina (3) · Australia (3) · Brazil (3) · France (3) · Netherlands (3) · Spain (3) · Switzerland (3) · Austria (2) · Belgium (2) · Czechia (2) · Israel (2) · Japan (2)
Marina Noris, PhD (2) · Diana Karpman (1) · Fernando C Fervenza, MD (1) · Gerald B Appel, MD (1)
PMID 42133432, PMID 22403278, PMID 33685975, PMID 41337715
2019 (1), 2023 (1)